Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vasogen sells US patent application
This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it
This device-based intellectual property has not been used to date in the Celacade System; however, Vasogen has retained rights to this technology for any potential use as it
Since 1998, Dr Morra has been a board member and consultant for various public and private life science companies. Dr Morra has previously served as the president of
The agreement grants Transgenomic exclusive rights in the US and certain international markets to neurodegenerative biomarkers from Power3 Medical, including NuroPro, a proposed diagnostic for Alzheimer’s and Parkinson’s
The company has reported net sales of $5.21 billion in the fourth quarter of 2008 that were essentially flat compared with the fourth quarter of 2007. For the
Dr Berman succeeds Robert Stote, who has been serving as the chief medical officer of Cpex since its spin-off from Bentley Pharmaceuticals in June 2008. Dr Stote, who
The new clinical development offices and expanded workforce will help Covance expedite the execution of clinical studies and build strategic relationships with investigators and sites in countries well
In his role at Quest, Leon held several positions over time, including director of molecular diagnostics, senior director of biotechnology department, and vice president of applied genomics. “We
MDX-1203 is comprised of a potent cytotoxic prodrug chemically linked with a fully human anti-CD70 antibody. CD70 is expressed in renal cell carcinoma (RCC), leukemias, lymphomas and other
Total revenue for the fourth quarter of 2008 increased to $31.2 million, compared with $19.3 million in the fourth quarter of 2007. Product revenue from the Oncotype DX(R)
Fiscal 2009 first quarter highlights Gross profit grew 5% to $15.3 million on increased sales and continued operating leverage. Effective tax rate declined to 33.6% due primarily to